IDiyas

For the Inventor, By the Inventor

The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.

The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.

Patent No.:

US 9815859 B1

PDFFull Text
Date of Patent:
Nov. 14, 2017

Filed:

May. 06, 2016

Tricyclic sulfones as rorγ modulators

Applicant:

Bristol-myers Squibb Company, Princeton, NJ (US);

Inventors:

Jingwu Duan, Yardley, PA (US);

T. G. Murali Dhar, Newtown, PA (US);

David Marcoux, Pennington, NJ (US);

Qing Shi, Princeton, NJ (US);

Douglas G. Batt, Wilmington, DE (US);

Qingjie Liu, Newtown, PA (US);

Robert J. Cherney, Newtown, PA (US);

Lyndon A. M. Cornelius, Jackson, NJ (US);

Anurag S. Srivastava, Belle Mead, NJ (US);

Myra Beaudoin Bertrand, Lambertville, NJ (US);

Carolyn A. Weigelt, Langhorne, PA (US);

Assignee:

Bristol-Myers Squibb Company, Princeton, NJ (US);

Attorney:

Elliott Korsen

Primary Examiner:

Pancham Bakshi

Int. Cl.
CPC ...
C07F 9/6574 (2006.01); C07D 215/36 (2006.01); C07D 409/04 (2006.01); C07D 417/04 (2006.01); C07D 209/30 (2006.01); C07D 209/60 (2006.01); C07D 209/70 (2006.01); C07D 221/10 (2006.01); C07D 401/06 (2006.01); C07D 401/12 (2006.01); C07D 403/06 (2006.01); C07D 403/12 (2006.01); C07D 405/06 (2006.01); C07D 409/06 (2006.01); C07D 413/06 (2006.01); C07D 413/10 (2006.01); C07D 413/12 (2006.01); C07D 417/06 (2006.01); C07D 417/12 (2006.01); C07D 417/14 (2006.01); C07D 471/04 (2006.01); C07D 491/052 (2006.01); C07D 491/107 (2006.01); C07D 493/08 (2006.01); C07D 495/04 (2006.01); C07D 495/08 (2006.01);
U.S. Cl.
CPC ...
C07F 9/65742 (2013.01); C07D 209/30 (2013.01); C07D 209/60 (2013.01); C07D 209/70 (2013.01); C07D 215/36 (2013.01); C07D 221/10 (2013.01); C07D 401/06 (2013.01); C07D 401/12 (2013.01); C07D 403/06 (2013.01); C07D 403/12 (2013.01); C07D 405/06 (2013.01); C07D 409/04 (2013.01); C07D 409/06 (2013.01); C07D 413/06 (2013.01); C07D 413/10 (2013.01); C07D 413/12 (2013.01); C07D 417/04 (2013.01); C07D 417/06 (2013.01); C07D 417/12 (2013.01); C07D 417/14 (2013.01); C07D 471/04 (2013.01); C07D 491/052 (2013.01); C07D 491/107 (2013.01); C07D 493/08 (2013.01); C07D 495/04 (2013.01); C07D 495/08 (2013.01);
Abstract

There are described RORγ modulators of the formula (I), and formula (II) or stereoisomers, tautomers, pharmaceutically acceptable salts, solvates, or prodrugs thereof, wherein all substituents are defined herein. Also provided are pharmaceutical compositions comprising the same. Such compounds and compositions are useful in methods for modulating RORγ activity in a cell and methods for treating a subject suffering from a disease or disorder in which the subject would therapeutically benefit from modulation of RORγ activity, for example, autoimmune and/or inflammatory disorders.

Find Patent Forward Citations

Loading…